Compass Therapeutics To Present Data On Novel Mechanism Of Action For CTX-10726 At 41st Society For Immunotherapy Of Cancer Annual Meeting

CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent cleavage of PD-1 receptors from T cells resulting in conversion of PD-1 positive T cells into PD-1 negative T cells. 

• PD-1 receptor cleavage by CTX-10726 was only observed in the presence of VEGF-A, suggesting targeted activity in the tumor microenvironment.
• A Phase 1 dose-escalation study of CTX-10726 in patients in the post-checkpoint setting with advanced solid tumors, including renal cell, gastroesophageal, endometrial, and hepatocellular cancers, is ongoing.
• In checkpoint inhibitor resistant preclinical mouse models, the combination of CTX-10726 and Compass’s CD137 agonist, CTX-471, inhibited tumor growth more than either agent alone.

BOSTON, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, will present data on the novel mechanism of action for CTX-10726 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting. CTX-10726 is currently in a Phase 1 dose-escalation study in patients in the post-checkpoint setting with multiple types of advanced solid tumors.